NURIX THERAPEUTICS, INC. (NRIX) Operating Margin
- Operating margin · 12 months: Value -982.37%; Formula and calculation Operating income / revenue. Period ending 2026-05-31..
Operating margin
Overview →Financial period ending 2026-05-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -982.37% | Operating income / revenue. Period ending 2026-05-31. $-361.18M ÷ $36.77M × 100 ≈ -982.37% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -361.18M USD | Operating Income (Loss) |
| Revenue | 36.77M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 340.93M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-05-31 | $-361.18M | $36.77M | (m) | $340.93M | (m) | -982.37% |
| 2026-02-28 | $-315.30M | $71.78M | (m) | $331.38M | (m) | -439.26% |
| 2025-11-30 | $-285.67M | $83.98M | (m) | $316.90M | (m) | -340.16% |
| 2025-08-31 | $-267.23M | $83.69M | (m) | $301.10M | (m) | -319.32% |
| 2025-05-31 | $-230.45M | $88.38M | (m) | $270.46M | (m) | -260.75% |
| 2025-02-28 | $-230.67M | $56.42M | (m) | $241.29M | (m) | -408.87% |
| 2024-11-30 | $-213.03M | $54.55M | (m) | $221.63M | (m) | -390.52% |
| 2024-08-31 | $-193.70M | $56.42M | (m) | $204.12M | (m) | -343.30% |
| 2024-05-31 | $-179.10M | $62.30M | (m) | $196.50M | (m) | -287.47% |
| 2024-02-29 | $-157.33M | $80.89M | (m) | $193.34M | (m) | -194.51% |
| 2023-11-30 | $-155.06M | $76.99M | (m) | $189.15M | (m) | -201.41% |
| 2023-08-31 | $-158.42M | $68.61M | (m) | $185.54M | (m) | -230.89% |
| 2023-05-31 | $-165.13M | $60.94M | (m) | $185.45M | (m) | -270.99% |
| 2023-02-28 | $-184.07M | $41.69M | (m) | $187.18M | (m) | -441.52% |
| 2022-11-30 | $-183.87M | $38.63M | (m) | $184.50M | (m) | -476.01% |
| 2022-08-31 | $-173.13M | $39.24M | (m) | $174.92M | (m) | -441.21% |
| 2022-05-31 | $-155.41M | $38.70M | (m) | $158.07M | (m) | -401.56% |
| 2022-02-28 | $-136.11M | $34.36M | (m) | $136.57M | (m) | -396.12% |
| 2021-11-30 | $-117.89M | $29.75M | (m) | $116.43M | (m) | -396.26% |
| 2021-08-31 | $-99.94M | $29.04M | (m) | $100.35M | (m) | -344.11% |
| 2021-05-31 | $-90.14M | $22.88M | (m) | $88.38M | (m) | -394.02% |
| 2021-02-28 | $-76.95M | $19.97M | (m) | $76.53M | (m) | -385.40% |
| 2020-11-30 | $-64.98M | $17.82M | (m) | $66.49M | (m) | -364.66% |
| 2020-08-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-05-31 | (m) | $19.49M | (m) | (m) | (m) | (m) |
| 2020-02-29 | (m) | $24.75M | (m) | (m) | (m) | (m) |
| 2019-11-30 | $-22.24M | $31.11M | (m) | $45.02M | (m) | -71.46% |
| 2019-08-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-05-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-02-28 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |